Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry.

AIMS The reported prevalence of angiotensin-converting enzyme (ACE) inhibitor use in patients with heart failure varies considerably. Recent reports suggest that many patients who could benefit from such therapy are not receiving ACE inhibitors. The Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry was established to understand better the demographics, characteristics, and contemporary use of ACE inhibitors in an international registry. METHODS AND RESULTS Between August 1996 and April 1997, each of 105 study centres from eight countries in North America and Europe was invited to review retrospectively the medical records of 100 consecutive patients with left ventricular ejection fractions </=35%. The median age of the 9580 Registry patients was 66 years, 26% were women, the median ejection fraction was 27%, and the primary aetiology of left ventricular dysfunction was ischaemic (63%). Eighty percent of patients were receiving ACE inhibitors. The most common reason for non-use of ACE inhibitors was intolerance (9%). CONCLUSION The SPICE Registry provides a contemporary description of the demographics and management of patients with documented left ventricular systolic dysfunction. The contemporary use of ACE inhibitors (80%) appears to be higher than previously reported and the main reason for non-use is perceived intolerance (9%).

[1]  W. Hall,et al.  Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy , 1992, Annals of Internal Medicine.

[2]  J. Wei,et al.  Age and the cardiovascular system. , 1992, The New England journal of medicine.

[3]  Mark A. Hlatky,et al.  Guidelines for the Evaluation and Management of Heart Failure Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) , 1995 .

[4]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[5]  E. Philbin,et al.  Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. , 1996, The American journal of cardiology.

[6]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[7]  H. Krause-Steinrauf,et al.  Where are all the women with heart failure? , 1997, Journal of the American College of Cardiology.

[8]  Investigators Seosi Survey on heart failure in Italian hospital cardiology units. Results of the SEOSI study. SEOSI Investigators. , 1997, European heart journal.

[9]  S. Yusuf,et al.  Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. , 1992, The American journal of cardiology.

[10]  J. Cohn,et al.  Effect of Enalapril, Hydralazine Plus Isosorbide Dinitrate, and Prazosin on Hospitalization in Patients With Chronic Congestive Heart Failure , 1993, Circulation.

[11]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[12]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[13]  C M O'Connor,et al.  Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. , 1997, Journal of the American College of Cardiology.

[14]  S. Yusuf,et al.  Natural history and patterns of current practice in heart failure , 1993 .

[15]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[16]  S. Yusuf,et al.  Patterns of Medication Use in Patients With Heart Failure: A Report From the Registry of Studies of Left Ventricular Dysfunction (SOLVD) , 1995, Southern medical journal.

[17]  B. Massie,et al.  Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. , 1997, American heart journal.

[18]  S. Fortmann,et al.  Differences in treatment of acute myocardial infarction by sex, age, and other factors (the Stanford Five-City Project). , 1996, The American journal of cardiology.

[19]  R. Carney,et al.  A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. , 1995, The New England journal of medicine.

[20]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[21]  D. Blumenthal,et al.  National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. , 1997, Archives of internal medicine.

[22]  W. Stevenson,et al.  Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. , 1995, Journal of the American College of Cardiology.

[23]  J. Hampton,et al.  Evidence of inadequate investigation and treatment of patients with heart failure. , 1994, British heart journal.

[24]  G. Hillis,et al.  Changing patterns of investigation and treatment of cardiac failure in hospital. , 1996, Heart.

[25]  J. Cohn,et al.  The management of chronic heart failure. , 1996, The New England journal of medicine.

[26]  W. Rogers,et al.  Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). , 1993, JAMA.

[27]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[28]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[29]  R. Califf,et al.  Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. , 1997, The American journal of cardiology.

[30]  M. Pfeffer,et al.  Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. , 1991, The New England journal of medicine.

[31]  S. Reis,et al.  Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. , 1997, Journal of the American College of Cardiology.

[32]  R. Doughty,et al.  Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.

[33]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[34]  J Z Ayanian,et al.  Differences in the use of procedures between women and men hospitalized for coronary heart disease. , 1991, The New England journal of medicine.

[35]  L Pilote,et al.  Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1995, The New England journal of medicine.

[36]  M. Pfeffer,et al.  Beta-adrenergic blockers and survival in heart failure. , 1996, The New England journal of medicine.

[37]  Y Wang,et al.  Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.

[38]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[39]  C. Nelson,et al.  Left Ventricular Function in Hospitalized Geriatric Patients , 1982, Journal of the American Geriatrics Society.

[40]  S. Yusuf,et al.  Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. , 1994, American heart journal.

[41]  K. Bailey,et al.  The incidence and prevalence of congestive heart failure in Rochester, Minnesota. , 1993, Mayo Clinic proceedings.

[42]  Eli Warnock,et al.  The effect of diltiazem on mortality and reinfarction after myocardial infarction. , 1989, The New England journal of medicine.

[43]  P E Leaverton,et al.  Prevalence and mortality rate of congestive heart failure in the United States. , 1992, Journal of the American College of Cardiology.

[44]  G. Lamas,et al.  Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. , 1992, The New England journal of medicine.

[45]  C. O'connor,et al.  Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. , 1997, The American journal of cardiology.

[46]  M B Weiss,et al.  Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. , 1996, American heart journal.